ADA

Fresh analysis spotlights cardio benefit of J&J's Invokana in diabetes patients without history of CV disease
Fresh analysis spotlights cardio benefit of J&J's Invokana in diabetes patients without history of CV disease
Endpoints
JNJ
Invokana
ADA
diabetes
cardiovascular disease
Flag link:
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
ADA: Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety study
Fierce Pharma
Eli Lilly
Boehringer Ingelheim
ADA
diabetes
Tradjenta
Flag link:
Sanofi's Soliqua Edges Out Competitors in Blood Sugar Control Trial
Sanofi's Soliqua Edges Out Competitors in Blood Sugar Control Trial
Biopharma Dive
Sanofi
diabetes
ADA
Soliqua
clinical trials
Flag link:
Provention’s Teplizumab Can Delay Onset of Type 1 Diabetes, Trial Results Show
Provention’s Teplizumab Can Delay Onset of Type 1 Diabetes, Trial Results Show
BioSpace
Povention Bio
clinical trials
type 1 diabetes
ADA
immunotherapy
Flag link:
ADA: AstraZeneca's Farxiga scores in kidney outcomes study
ADA: AstraZeneca's Farxiga scores in kidney outcomes study
Fierce Pharma
AstraZeneca
ADA
Farxiga
clinical trials
renal disease
Flag link:
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Lilly plans phase 2b NASH trial of dual GIP, GLP-1 agonist
Fierce Biotech
Eli Lilly
NASH
tirzepatide
clinial trials
ADA
type 2 diabetes
Flag link:
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
ADA: Lilly's Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Fierce Pharma
Eli Lilly
ADA
diabetes
heart attack
stroke
Trulicity
Novo Nordisk
semaglutide
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
Insulin Patch Earns Spot in American Diabetes Association Guidelines for Diabetes Care
Insulin Patch Earns Spot in American Diabetes Association Guidelines for Diabetes Care
Xtalks
diabetes
type 2 diabetes
insulin patch
ADA
Valeritas
V-Go
devices
Flag link:
Diabetes group nods to Vascepa, sending Amarin stock higher
Diabetes group nods to Vascepa, sending Amarin stock higher
Biopharma Dive
ADA
Vascepa
Amarin
diabetes
Flag link:
25 European medtech and life sciences start-ups to watch in 2019
25 European medtech and life sciences start-ups to watch in 2019
Silicon Republic
Europe
devices
startups
ADA
Ava
Aiforia
Bambi Medical
BioBeats
BrainWave Bank
Diaceutics
Dobco Medical Systems
Doctena
Etsimo
Fluidic Analytics
Heartbeat Medical
HealthBeacon
Healthera
Healx
Kite Medical
Medherant
Neurent Medical
Nuritas
Oura
Sword Health
UgenTec
WhiteSwell
Ultromics
Xeltis
Flag link:
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
NASDAQ.com
Amgen
Repatha
type 2 diabetes
diabetes
hypercholesterolemia
ADA
Flag link:
ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study
ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study
Fierce Pharma
Eli Lilly
Trulicity
diabetes
Novo Nordisk
Victoza
AstraZeneca
Bydureon
ADA
Flag link:
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
Fierce Pharma
ADA
kidney disease
Eli Lilly
Boehringer Ingelheim
Flag link:
ADA preview: 5 things to watch in diabetes
ADA preview: 5 things to watch in diabetes
BioPharma Dive
ADA
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Lantus
Tresiba
JNJ
Novo Nordisk
PCSK9 inhibitors
Amgen Regeneron
Sanofi
Apple
Google
insulin
Flag link:
ADA guidelines highlight new Jardiance label
ADA guidelines highlight new Jardiance label
BioPharma Dive
ADA
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Novo Nordisk
Victoza
Flag link:
Who Got The Most Buzz At The Diabetes Show?
Who Got The Most Buzz At The Diabetes Show?
Pharmalot
ADA
diabetes
JNJ
Eli Lilly
Novo Nordisk
Sanofi
Bristol-Myers Squibb
Flag link:
Sanofi, Novo Nordisk, Amylin all tout diabetes treatments at ADA
Sanofi, Novo Nordisk, Amylin all tout diabetes treatments at ADA
Fierce Pharma
Sanofi
Novo Nordisk
ADA
diabetes
Amylin
degludec
Lantus
Victoza
Flag link:
Research Presented at ADA Adds to the Clinical Evidence for Medtronic’s Sensor-Augmented Insulin Pump Therapy
Research Presented at ADA Adds to the Clinical Evidence for Medtronic’s Sensor-Augmented Insulin Pump Therapy
research
ADA
clinical
Medtronic
Flag link:
ADA diabetes roundup: Is surgery the answer?
ADA diabetes roundup: Is surgery the answer?
ADA
diabetes
surgery
Flag link:

Pages